Amylyx Pharmaceuticals (AMLX)

• Market cap: $770M
• 1 day: 1.53%
• 5 days: 10.36%
• 1 month: 8.01%
• 3 months: 82.84%
• 6 months: 169.69%
• Year to date: 120.72%
• 1 year: 290.50%
• 5 years: -52.24%
• 10 years: -52.24%
• Sector: Healthcare
• Industry: Biotechnology

About: Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.

Employees: 123

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

3,241% more call options, than puts

Call options by funds: $568K | Put options by funds: $17K

500% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 6 (+5) [Q2]

100% more capital invested

Capital invested by funds: $262M [Q1] → $523M (+$261M) [Q2]

8.11% more ownership

Funds ownership: 83.38% [Q1] → 91.5% (+8.11%) [Q2]

0% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 36

4% less funds holding

Funds holding: 134 [Q1] → 128 (-6) [Q2]

11% less first-time investments, than exits

New positions opened: 32 | Existing positions closed: 36

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $10 16% upside
• Avg. target: $13 51% upside
• High target: $17 97% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Goldman Sachs Corinne Johnson	16% upside $10	Buy Reinstated	10 Jul 2025
Guggenheim Seamus Fernandez	97% upside $17	Buy Initiated	24 Jun 2025
Citigroup Geoff Meacham	39% upside $12	Buy Initiated	17 Jun 2025